Drug Profile
Research programme: protein therapeutics - Virvio
Alternative Names: HB36.6Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Virvio
- Developer The Scripps Research Institute; University of Washington; Utah State University; Virvio
- Class Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 27 Sep 2023 NDR#29 - Kdm, intro and dev line reverted and ADS added. Company pipeline is not accessible - (University of Washington website, September 2023)
- 27 Sep 2023 Reasearch programme for protein therapeutics is still in preclinical development in Influenza-virus-infections in USA (Intranasal, Inhalant) (University of Washington website, September 2023)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Intranasal, Inhalant)